TenX Biopharma To Conduct Clinical Study With The National Cancer Institute

Main Category: Cancer / Oncology
Also Included In: Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 30 Apr 2010 - 3:00 PDT

email to a friend   printer friendly   opinions  

TenX Biopharma, Inc., announced it has signed a Clinical Trial Agreement with the National Cancer Institute (NCI) to conduct an investigator sponsored Phase II clinical trial.

For this study, the NCI's Surgery Branch Chief, Dr. Steven A. Rosenberg, will lead a Phase II clinical trial investigating the combination of TenX Biopharma's zanolimumab, an investigational anti-CD4 therapeutic antibody, with aldesleukin (IL-2) for the treatment of metastatic melanoma and renal cell carcinoma.

"The activity of zanolimumab in combination treatments for cancer may provide a new therapeutic option to help patients counter these aggressive diseases. This initiative under Dr. Rosenberg at the NCI to generate additional data will contribute significantly to the field of immune modulation in oncology," said Gardiner Smith, CEO of TenX Biopharma.

"We are delighted that TenX is participating in such an important trial, which may have far reaching implications for zanolimumab in cancer therapeutics beyond its current use with T cell lymphomas," said Asher Nathan, President of TenX Biopharma.

Zanolimumab is hoped to reduce CD4+ T regulatory cells, and may increase therapeutic effectiveness of IL-2, which is an approved therapy.

About TenX

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab (CO:GEN) in conjunction with a financing led by Zoticon Bioventures.

This press release contains forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. TenX Biopharma does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Source: TenX Biopharma, Inc

• Additional
• References
• Citations